Sam J Lubner

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study
    Sam J Lubner
    University of Wisconsin, Madison, WI 53792, USA
    J Clin Oncol 28:3491-7. 2010
  2. ncbi A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer
    Sam J Lubner
    University of Wisconsin Carbone Cancer Center, Madison, USA
    Clin Colorectal Cancer 9:157-61. 2010
  3. ncbi A preclinical and clinical study of lithium in low-grade neuroendocrine tumors
    Sam J Lubner
    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
    Oncologist 16:452-7. 2011
  4. ncbi A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma
    Tabraiz A Mohammed
    D O, M S, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, Wisconsin 53792, USA
    Oncologist 16:835-43. 2011

Detail Information

Publications4

  1. ncbi Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study
    Sam J Lubner
    University of Wisconsin, Madison, WI 53792, USA
    J Clin Oncol 28:3491-7. 2010
    ..Secondary end points included overall survival (OS), time to progression (TTP), VEGF levels, and molecular studies of EGFR and k-ras...
  2. ncbi A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer
    Sam J Lubner
    University of Wisconsin Carbone Cancer Center, Madison, USA
    Clin Colorectal Cancer 9:157-61. 2010
    ..This phase II study explores the efficacy and safety of a 2-day course of oxaliplatin/capecitabine (2DOC), with oxaliplatin given on day 1 and capecitabine given orally every 8 hours in high doses over 6 doses, mimicking FOLFOX6...
  3. ncbi A preclinical and clinical study of lithium in low-grade neuroendocrine tumors
    Sam J Lubner
    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
    Oncologist 16:452-7. 2011
    ..Use of lithium chloride in murine models suppressed carcinoid cell growth, reduced GSK-3β levels, and reduced expression of chromogranin A. This study assessed the efficacy of lithium chloride in patients with NETs...
  4. ncbi A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma
    Tabraiz A Mohammed
    D O, M S, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, Wisconsin 53792, USA
    Oncologist 16:835-43. 2011
    ..Thus, this study aimed to evaluate the role of VPA in treating NETs and to determine whether VPA induced the Notch signaling pathway signaling in vivo...